RBCs Induce Necroptosis of Lung Endothelial Cells and Increase Susceptibility to Lung Inflammation Researchers set out to determine the mechanisms of lung EC High Mobility Group Box 1 (HMGB1) release following exposure to RBCs and to determine whether RBC transfusion increases susceptibility to lung inflammation in vivo through release of the danger signal HMGB1. [Am J Respir Crit Care Med] Abstract Resolvin D1 Attenuates Polyinosinic-Polycytidylic Acid-Induced Inflammatory Signaling in Human Airway Epithelial Cells via TAK1 Investigators identified the mechanism whereby resolvin D1 disrupts inflammatory mediator production induced by the viral mimic polyinosinic-polycytidylic acid in primary human lung epithelial cells. [J Immunol] Abstract Superiority of Combined PDE3/PDE4 Inhibition Over PDE4 Inhibition Alone on Glucocorticoid- and Long-Acting β2-Adrenoceptor Agonist-Induced Gene Expression in Human Airway Epithelial Cells Using models of cAMP- and glucocorticoid-induced transcription in human bronchial epithelial BEAS-2B cells, researchers show that combining inhibitors of phosphodiesterase (PDE) 3 and PDE4 provides greater benefits compared to inhibiting either PDE alone. [Mol Pharmacol] Abstract | Full Article Enhanced Phenotypic Alterations of Alveolar Type II Cells in Response to Aflatoxin G1-Induced Lung Inflammation Increased MHC-II expression in alveolar epithelium was observed and associated with enhanced T cells (Tregs) infiltration in mouse lung tissues with Aflatoxin G1 (AFG1)-induced inflammation. This provides a link between phenotypically altered alveolar type II cells and Treg activity in the AFG1-induced inflammatory microenvironment. [J Cell Physiol] Abstract Therapeutic Effects of Amniotic Fluid-Derived Mesenchymal Stromal Cells on Lung Injury in Rats with Emphysema Researchers analyzed the phenotypic characteristics, differentiation potential, and karyotype of rat amniotic fluid-derived mesenchymal stromal cells (rAFMSCs), which were isolated from pregnant Sprague-Dawley rats. The ability of rAFMSCs to differentiate was measured, and the apoptosis of type II alveolar epithelial cells was evaluated. [Resp Res] Full Article LUNG CANCER A Novel Antagonist to the Inhibitors of Apoptosis (IAPs) Potentiates Cell Death in EGFR-Overexpressing Non-Small-Cell Lung Cancer Cells In the effort to develop an efficient chemotherapy drug for the treatment of non-small-cell lung cancer (NSCLC), scientists analyzed the anti-tumorigenic effects of a novel small molecule targeting the inhibitor of apoptosis, HM90822B, on NSCLC cells. HM90822B efficiently decreased IAP expression, especially that of XIAP and survivin, in several NSCLC cells. [Cell Death Dis] Full Article Mcl-1 Promotes Lung Cancer Cell Migration by Directly Interacting with VDAC to Increase Mitochondrial Ca2+ Uptake and Reactive Oxygen Species Generation Scientists report the physiological significance of an interaction between Mcl-1 and the mitochondrial outer membrane-localized voltage-dependent anion channel (VDAC) in non-small cell lung carcinoma cell lines. [Cell Death Dis] Full Article Mast Cell Exosomes Promote Lung Adenocarcinoma Cell Proliferation – Role of KIT-Stem Cell Factor Signaling The authors demonstrate that exosomes from mast cells can be taken up by lung cancer cells. Exosomes were isolated from the human mast cell line, HMC-1, and uptake of PKH67-labelled exosomes by the lung epithelial cell line, A549, was examined using flow cytometry and fluorescence microscopy. [Cell Commun Signal] Full Article Critical Role of Spns2, a Sphingosine-1-Phosphate Transporter, in Lung Cancer Cell Survival and Migration Researchers show that ectopic Spns2 expression induced apoptosis and its knockdown enhanced cell migration in non-small cell lung cancer cells. [PLoS One] Full Article Effects of AKT Inhibition on HGF-Mediated Erlotinib Resistance in Non-Small Cell Lung Cancer Cell Lines Investigators determined whether inhibition of AKT signaling could augment erlotinib activity and abrogate HGF-mediated resistance. The effects of MK-2206, a selective AKT inhibitor, were evaluated in combination with erlotinib on a large panel of 13 lung cancer cell lines containing different EGFR or KRAS abnormalities. [J Cancer Res Clin Oncol] Abstract |